

## Medical Coverage Policy | Risk Reducing Mastectomy



**EFFECTIVE DATE:** 06|01|2001

**POLICY LAST UPDATED:** 05|04|2022

### OVERVIEW

Risk-reducing mastectomy is defined as the removal of the breast in the absence of malignant disease to reduce the risk of breast cancer occurrence.

### MEDICAL CRITERIA

Not applicable

### PRIOR AUTHORIZATION

Not applicable

### POLICY STATEMENT

#### Medicare Advantage Plans and Commercial Products

Risk reducing mastectomy is considered medically necessary in patients at high risk of breast cancer

### COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable surgery benefits/coverage.

### BACKGROUND

Risk-reducing mastectomy may be considered in women thought to be at high-risk of developing breast cancer, either due to family history, presence of genetic variants (eg, BRCA1, BRCA2), having received radiotherapy to the chest, or the presence of lesions associated with an increased cancer risk such as lobular carcinoma in situ. Therefore, bilateral risk-reducing mastectomy may be performed to eliminate the risk of cancer arising elsewhere; chemoprevention and close surveillance are alternative risk-reduction strategies. Risk-reducing mastectomies are typically bilateral but can also describe a unilateral mastectomy in a patient who has previously undergone or is currently undergoing a mastectomy in the opposite breast for invasive cancer (ie, contralateral risk-reducing mastectomy). Use of contralateral risk-reducing mastectomy has increased in the U.S. An analysis of data from the National Cancer Database found that the rate of contralateral risk-reducing mastectomy in women diagnosed with unilateral stage I, II, or III breast cancer increased from approximately 4% in 1998 to 9.4% in 2002.<sup>1</sup>

The appropriateness of a risk-reducing mastectomy is a complicated risk-benefit analysis that requires estimates of a patient's risk of breast cancer, typically based on the patient's family history of breast cancer and other factors. Several models are available to assess risk of breast cancer.<sup>2</sup> The specific risk factors included in the models vary, but all incorporate characteristics related to age, reproductive history, and family history. In addition to the patient's risk assessment, the choice of a risk-reducing mastectomy is based on patient tolerance for risk, consideration of changes to appearance and need for additional cosmetic surgery, and the risk-reduction offered by mastectomy versus other options.

It is strongly recommended that all candidates for risk-reducing mastectomy undergo counseling regarding cancer risks from a health professional skilled other than the operating surgeon to assess cancer risk and to discuss various treatment options, including increased surveillance or chemoprevention with tamoxifen or raloxifene.

There is no standardized method for determining a woman's risk of breast cancer that incorporates all possible risk factors. There are validated risk prediction models, but they are based primarily on family history.

Some known individual risk factors confer a high risk by themselves. The following list includes factors known to indicate a high risk of breast cancer:

- lobular carcinoma in situ,
- a known *BRCA1* or *BRCA2* variant,
- another gene variant associated with high risk, eg, *TP53* (Li-Fraumeni syndrome), *PTEN* (Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome), *CDH1*, and *STK11*, or
- received radiotherapy to the chest between 10 and 30 years of age.

A number of other factors may increase the risk of breast cancer but do not by themselves indicate high risk (generally considered to be a lifetime risk of  $\geq 20\%$ ). It is possible that combinations of these factors may be indicative of high risk, but it is not possible to give quantitative estimates of risk. As a result, it may be necessary to individualize the estimate of risk by taking into account numerous risk factors. A number of risk factors, not individually indicating high risk, are included in the National Cancer Institute Breast Cancer Risk Assessment Tool, also called the Gail model.

Another breast cancer risk assessment tool, used in the Women Informed to Screen Depending on Measures of Risk trial, is the Breast Cancer Surveillance Consortium (BCSC) Risk Calculator (<https://tools.bcscc.org/bc5yearrisk/calculator.htm>). The following information is used in that assessment tool:

- History of breast cancer, ductal carcinoma in situ, breast augmentation, or mastectomy
- Age/Race/ethnicity
- Number of first-degree relatives (mother, sister, or daughter) diagnosed with breast cancer
- Prior breast biopsies (positive or negative)
- BI-RADS breast density (radiologic assessment of breast tissue density by radiologists who interpret mammograms)

### **Practice Guidelines and Position Statements**

#### **American Society for Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology**

The Society of Surgical Oncology (2017) updated its position statement on risk-reducing mastectomy. The position statement concluded the following about risk-reducing mastectomy:

"There is no single-risk threshold above which risk-reducing mastectomy is clearly indicated, and it is important for treating physicians and surgeons to explain to individuals not only the risk assessment but also all available treatment strategies to facilitate a shared decision-making process."

"The available data suggest that BMP [bilateral prophylactic mastectomy] confers a survival advantage in women with the highest risk who undergo the procedure at a relatively early age ... the impact of CPM [contralateral prophylactic mastectomy] in women with invasive breast cancer is more difficult to assess ... however, CPM does not appear to confer a survival advantage."

#### **American Society for Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology**

In 2020, the American Society for Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology published joint guidelines on management of hereditary breast cancer.<sup>19</sup> The guideline discusses management of patients with breast cancer with germline mutations in breast cancer susceptibility genes (eg, *BRCA1/2*, *ATM*, *TP53*) and makes the following recommendations regarding risk-reducing mastectomy:

"Surgical management of the index malignancy (... contralateral risk-reducing mastectomy [CRRM]) in *BRCA1/2* mutation carriers should be discussed, considering the increased risk of CBC and possible

increased risk of an ipsilateral new primary breast cancer compared with noncarriers (Type: formal consensus; Evidence quality: intermediate; Strength of recommendation: strong)."

"For women with breast cancer who have a *BRC A1/2* mutation and who have been treated or are being treated with unilateral mastectomy, CRRM should be offered. CRRM is associated with a decreased risk of CBC; there is insufficient evidence for improved survival."

"Decisions regarding risk-reducing mastectomy (bilateral or contralateral) are highly personal and must be individualized for every patient. Studies show that women who opt for prophylactic mastectomy report positive outcomes, including decreased concern about developing breast cancer. This benefit must be weighed against possible problems with implants or reconstructive therapy and potential adverse feelings related to body image, femininity, and sexuality. Most patients who opt for prophylactic mastectomy demonstrate satisfaction with their decision."

"For women with breast cancer who have a mutation in a moderate-penetrance breast cancer predisposition gene and who have been treated or are being treated with unilateral mastectomy, the decision regarding [contralateral risk-reducing mastectomy] CRRM should not be based predominantly on mutation status. Additional factors that predict CBC such as age at diagnosis and family history should be considered, as they are in all cases. The impact of CRRM on decreasing risk of CBC is dependent on the risk of CBC for each individual gene. Data regarding the risk of CBC resulting from moderate-penetrance genes are limited (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate)."

The guideline also provides recommendations for assessing the risk of CBC and role of risk-reducing mastectomy in *BRC A1/2* mutation carriers (Evidence quality: low; Strength of recommendation: moderate) and in women with breast cancer who have a *BRC A1/2* mutation who have been treated or are being treated with unilateral mastectomy when considering contralateral risk-reducing mastectomy (Evidence quality: intermediate; Strength of recommendation: moderate). The guideline recommends consideration of the following:

- Age at diagnosis (the strongest predictor of future CBC)
- Family history of breast cancer
- Overall prognosis from this or other cancers (eg, ovarian)
- Ability of patient to undergo appropriate breast surveillance (magnetic resonance imaging [MRI])
- Comorbidities
- Life expectancy.

### **Society of Surgical Oncology**

In 2017, the Society of Surgical Oncology updated its position statement on risk-reducing mastectomy.<sup>20</sup> The position statement concluded the following about risk-reducing mastectomy:

"There is no single-risk threshold above which risk-reducing mastectomy is clearly indicated, and it is important for treating physicians and surgeons to explain to individuals not only the risk assessment but also all available treatment strategies to facilitate a shared decision-making process."

"The available data suggest that BMP [bilateral prophylactic mastectomy] confers a survival advantage in women with the highest risk who undergo the procedure at a relatively early age ... the impact of CPM [contralateral prophylactic mastectomy] in women with invasive breast cancer is more difficult to assess ... however, CPM does not appear to confer a survival advantage."

### **National Cancer Institute**

In 2013, the National Cancer Institute updated its fact sheet on risk-reducing surgery for breast cancer.<sup>21</sup> The fact sheet stated women with the following characteristics may consider bilateral risk-reducing mastectomy:

- Deleterious variant in *BRC A1* or *BRC A2*

- Strong family history of breast cancer
- Lobular carcinoma in situ and family history of breast cancer
- Radiotherapy to the chest before the age of 50 years.

Considering contralateral risk-reducing mastectomy, the Institute stated: "Given that most women with breast cancer have a low risk of developing the disease in their contralateral breast, women who are not known to be at a very high risk but who remain concerned about cancer development in their other breast may want to consider options other than surgery to further reduce their risk of a contralateral breast cancer."

### American Society of Breast Surgeons

In 2016, a consensus statement from the American Society of Breast Surgeons made the following recommendations on contralateral risk-reducing mastectomy<sup>22</sup>:

"CPM [contralateral prophylactic mastectomy] should be considered for those at significant risk of CBC [contralateral breast cancer]

- Documented *BRCA1/2* carrier
- Strong family history, but patient has not undergone genetic testing
- History of mantle chest radiation before age 30 years.

CPM can be considered for those at lower risk of CBC

- Gene carrier of... *CHEK-2, PALB2, p53, CDH1*
- Strong family history, patient *BRCA* negative, no known *BRCA* family member.

CPM may be considered for other reasons

- To limit contralateral breast surveillance (dense breasts, failed surveillance, recall fatigue)
- To improve reconstructed breast symmetry
- To manage risk aversion ... [or] extreme anxiety." (note: anxiety may be better managed through psychological support strategies.)

CPM should be discouraged

- Average-risk women with unilateral breast cancer
- Women with advanced index cancer
- Women at high risk for surgical complications (e.g.,...comorbidities, obesity, smoker , diabetes)
- *BRCA* negative with a family of *BRCA*-positive carriers
- Male breast cancer, including *BRCA* carriers.
- 

### National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) has made recommendations on several cancers relevant to this evidence review. On breast cancer risk-reduction (v.1.2021 ), the NCCN recommends:

"Risk-reducing mastectomy should generally be considered only in women with a pathogenic/likely pathogenic genetic mutation (not variants of undetermined significance) conferring a high risk for breast cancer..., compelling family history, or possibly with prior thoracic RT [radiation therapy] at <30 years of age. The value of risk-reducing mastectomy in individuals with pathogenic/likely pathogenic mutations in other genes associated with a 2-fold or greater risk for breast cancer ... in the absence of a compelling family history of breast cancer is unknown."<sup>23</sup>

For invasive breast cancer (v.4.2021 ) the NCCN has discouraged contralateral risk-reducing mastectomy, except for certain high-risk situations (noted in the risk-reduction guideline previously discussed).<sup>24</sup> The guidelines state:

"....risk reduction mastectomy of a breast contralateral to a known unilateral breast cancer treated with mastectomy is discouraged by the panel. The use of a prophylactic mastectomy contralateral to a breast treated with lumpectomy is very strongly discouraged in all patients."

As part of a genetic/familial high-risk assessment for breast, ovarian, and pancreatic cancer (v.1.2021 ), the NCCN recommends that the option of risk-reduction mastectomy be discussed in women with *BRCA*-related breast and/or ovarian syndrome, Li-Fraumeni syndrome, and Cowden syndrome or *PTEN* hamartoma tumor syndrome.<sup>25</sup> In addition, the NCCN guidelines recommend that risk-reducing mastectomy be considered based on family history in women with certain genetic variants including *ATM*, *PALB2*, *CHEK2*, and *CDH1*.

## **CODING**

### **Medicare Advantage Plans and Commercial Products**

The following code(s) are covered;

**19303** Mastectomy, simple, complete

**19304** Mastectomy, subcutaneous

## **RELATED POLICIES**

None

## **PUBLISHED**

Provider Update, July 2022

Provider Update, May 2021

Provider Update, May 2020

Provider Update, July 2017

Provider Update, January 2017

## **REFERENCES**

1. Yao K, Winchester DJ, Czechura T, et al. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002. *Breast Cancer Res Treat.* Dec 2013; 142(3): 465-76. PMID 24218052
2. McCarthy AM, Guan Z, Welch M, et al. Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort. *J Natl Cancer Inst.* May 01 2020; 112(5): 489-497. PMID 31556450
- Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Bilateral prophylactic mastectomy in women with an increased risk of breast cancer. *TEC Assessments.* 1999;14:Tab 14.
3. Li X, You R, Wang X, et al. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review. *Clin Cancer Res.* Aug 01 2016; 22(15): 3971-81. PMID 26979395
4. Ludwig KK, Neuner J, Butler A, et al. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. *Am J Surg.* Oct 2016; 212(4): 660-669. PMID 27649974
5. Honold F, Camus M. Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women's BRCA carriers. *Medwave.* Jul 09 2018; 18(4): e7161. PMID 30052622
6. Carbine NE, Lostumbo L, Wallace J, et al. Risk-reducing mastectomy for the prevention of primary breast cancer. *Cochrane Database Syst Rev.* Apr 05 2018; 4: CD002748. PMID 29620792
7. Nichols HB, Berrington de Gonzalez A, Lacey JV, et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. *J Clin Oncol.* Apr 20 2011; 29(12): 1564-9. PMID 21402610
8. Molina-Montes E, Perez-Nevot B, Pollan M, et al. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. *Breast.* Dec 2014; 23(6): 721-42. PMID 25467311
9. Fayanju OM, Stoll CR, Fowler S, et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. *Ann Surg.* Dec 2014; 260(6): 1000-10. PMID 24950272
10. Kurian AW, Canchola AJ, Ma CS, et al. Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. *Cancer.* Mar 01 2020; 126(5): 958-970. PMID 31750934
11. Wong SM, Freedman RA, Sagara Y, et al. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. *Ann Surg.* Mar 2017; 265(3): 581-589. PMID 28169929



12. Kruper L, Kauffmann RM, Smith DD, et al. Survival analysis of contralateral prophylactic mastectomy: a question of selection bias. *Ann Surg Oncol*. Oct 2014; 21(11): 3448-56. PMID 25047478
13. Pesce C, Liederbach E, Wang C, et al. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. *Ann Surg Oncol*. Oct 2014; 21(10): 3231-9. PMID 25081341
14. Schroeder MC, Tien YY, Erdahl LM, et al. The relationship between contralateral prophylactic mastectomy and breast reconstruction, complications, breast-related procedures, and costs: A population-based study of health insurance data. *Surgery*. Nov 2020; 168(5): 859-867. PMID 32819721
15. Silva AK, Lapin B, Yao KA, et al. The Effect of Contralateral Prophylactic Mastectomy on Perioperative Complications in Women Undergoing Immediate Breast Reconstruction: A NSQIP Analysis. *Ann Surg Oncol*. Oct 2015; 22(11): 3474-80. PMID 26001862
16. Miller ME, Czechura T, Martz B, et al. Operative risks associated with contralateral prophylactic mastectomy: a single institution experience. *Ann Surg Oncol*. Dec 2013; 20(13): 4113-20. PMID 23868655
17. Eck DL, Perdakis G, Rawal B, et al. Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy. *Ann Surg Oncol*. Oct 2014; 21(10): 3297-303. PMID 25047470
18. Tung NM, Boughey JC, Pierce LJ, et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. *J Clin Oncol*. Jun 20 2020; 38(18): 2080-2106. PMID 32243226
19. Hunt KK, Euhus DM, Boughey JC, et al. Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. *Ann Surg Oncol*. Feb 2017; 24(2): 375-397. PMID 27933411
20. National Cancer Institute. Fact Sheet: Surgery to Reduce the Risk of Breast Cancer. 2013; <https://www.cancer.gov/types/breast/risk-reducing-surgery-fact-sheet>. Accessed May 2020.
21. Boughey JC, Attai DJ, Chen SL, et al. Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks. *Ann Surg Oncol*. Oct 2016; 23(10): 3100-5. PMID 27469117
22. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. Version 1.2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast\\_risk.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf). Accessed May 21, 2021.
23. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). Accessed May 21, 2021.
24. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/genetics\\_screening.pdf](https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf) Accessed May 21, 2021.

**CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS**

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

